{"count": 19, "results": [{"_id": "36142447", "pmid": 36142447, "pmcid": "PMC9503052", "title": "Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)3-Functionalized PEG-PLGA Biopolymer Encapsulating Simvastatin for the Treatment of Osteoporosis in Rat Models", "journal": "Int J Mol Sci", "authors": ["Lin CW", "Lee CY", "Lin SY", "Kang L", "Fu YC", "Chen CH", "Wang CK"], "date": "2022-09-11T00:00:00Z", "doi": "10.3390/ijms231810530", "meta_date_publication": "2022 Sep 11", "meta_volume": "23", "meta_issue": "18", "meta_pages": "", "score": 50268.01, "text_hl": "...@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ (@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SIM@@@) is a @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipid@@@-lowering drug that also promotes bone formation, but its high liver specificity may cause @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@, and the low solubility of lipophilic drugs limits the systemic administration of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SIM@@@, especially in @DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@osteoporosis@@@ (@DISEASE_Osteoporosis @DISEASE_MESH:D010024 @@@OP@@@) studies. ", "citations": {"NLM": "Lin CW, Lee CY, Lin SY, Kang L, Fu YC, Chen CH, Wang CK. Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)3-Functionalized PEG-PLGA Biopolymer Encapsulating Simvastatin for the Treatment of Osteoporosis in Rat Models Int J Mol Sci. 2022 Sep 11;23(18):. PMID: 36142447", "BibTeX": "@article{36142447, title={Bone-Targeting Nanoparticles of a Dendritic (Aspartic acid)3-Functionalized PEG-PLGA Biopolymer Encapsulating Simvastatin for the Treatment of Osteoporosis in Rat Models}, author={Lin CW and Lee CY and Lin SY and Kang L and Fu YC and Chen CH and Wang CK}, journal={Int J Mol Sci}, volume={23}, number={18}}"}}, {"_id": "33034787", "pmid": 33034787, "title": "Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue.", "journal": "Cell Biol Toxicol", "authors": ["Wang L", "Zheng ZG", "Meng L", "Zhu L", "Li P", "Chen J", "Yang H"], "date": "2021-06-01T00:00:00Z", "doi": "10.1007/s10565-020-09558-w", "meta_date_publication": "2021 Jun", "meta_volume": "37", "meta_issue": "3", "meta_pages": "441-460", "score": 50266.062, "text_hl": "Graphical headlights 1. @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ induces @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@skeletal muscle atrophy@@@ via increasing serum @GENE_MSTN @GENE_17700 @@@myostatin@@@ levels in @SPECIES_10090 @@@mice@@@; 2. ", "citations": {"NLM": "Wang L, Zheng ZG, Meng L, Zhu L, Li P, Chen J, Yang H. Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue. Cell Biol Toxicol. 2021 Jun;37(3):441-460. PMID: 33034787", "BibTeX": "@article{33034787, title={Statins induce skeletal muscle atrophy via GGPP depletion-dependent myostatin overexpression in skeletal muscle and brown adipose tissue.}, author={Wang L and Zheng ZG and Meng L and Zhu L and Li P and Chen J and Yang H}, journal={Cell Biol Toxicol}, volume={37}, number={3}, pages={441-460}}"}}, {"_id": "33222146", "pmid": 33222146, "title": "Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice.", "journal": "Mol Neurobiol", "authors": ["Wang Y", "Bai L", "Li S", "Wen Y", "Liu Q", "Li R", "Liu Y"], "date": "2021-04-01T00:00:00Z", "doi": "10.1007/s12035-020-02216-6", "meta_date_publication": "2021 Apr", "meta_volume": "58", "meta_issue": "4", "meta_pages": "1593-1606", "score": 50258.63, "text_hl": "Together, our findings highlighted that @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ exacerbated skeletal @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle atrophy@@@ and denervation in spite of promoting myogenesis in damaged muscle, providing new insights into the selective use of statin-induced @DISEASE_Muscular_Diseases @DISEASE_MESH:D009135 @@@myopathy@@@ in @DISEASE_Liver_Neoplasms @DISEASE_MESH:D008113 @@@ALS@@@.", "citations": {"NLM": "Wang Y, Bai L, Li S, Wen Y, Liu Q, Li R, Liu Y. Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice. Mol Neurobiol. 2021 Apr;58(4):1593-1606. PMID: 33222146", "BibTeX": "@article{33222146, title={Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice.}, author={Wang Y and Bai L and Li S and Wen Y and Liu Q and Li R and Liu Y}, journal={Mol Neurobiol}, volume={58}, number={4}, pages={1593-1606}}"}}, {"_id": "34990819", "pmid": 34990819, "title": "Dynamic urine proteome changes in a rat model of simvastatin-induced skeletal muscle injury.", "journal": "J Proteomics", "authors": ["Wei J", "Huan Y", "Heng Z", "Zhao C", "Jia L", "Yu Y", "Gao Y"], "date": "2022-03-15T00:00:00Z", "doi": "10.1016/j.jprot.2021.104477", "meta_date_publication": "2022 Mar 15", "meta_volume": "254", "meta_issue": "", "meta_pages": "104477", "score": 50256.66, "text_hl": "SIGNIFICANCE: This study demonstrate that the early @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@ caused by @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ can be reflected in urinary proteins. ", "citations": {"NLM": "Wei J, Huan Y, Heng Z, Zhao C, Jia L, Yu Y, Gao Y. Dynamic urine proteome changes in a rat model of simvastatin-induced skeletal muscle injury. J Proteomics. 2022 Mar 15;254():104477. PMID: 34990819", "BibTeX": "@article{34990819, title={Dynamic urine proteome changes in a rat model of simvastatin-induced skeletal muscle injury.}, author={Wei J and Huan Y and Heng Z and Zhao C and Jia L and Yu Y and Gao Y}, journal={J Proteomics}, volume={254}, pages={104477}}"}}, {"_id": "32230890", "pmid": 32230890, "pmcid": "PMC7180799", "title": "Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway", "journal": "Molecules", "authors": ["Won KJ", "Goh YJ", "Hwang SH"], "date": "2020-03-27T00:00:00Z", "doi": "10.3390/molecules25071529", "meta_date_publication": "2020 Mar 27", "meta_volume": "25", "meta_issue": "7", "meta_pages": "", "score": 50255.68, "text_hl": "...Statins such as @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ have many side effects, including @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@, which is known to be the most frequent undesirable side effect. ", "citations": {"NLM": "Won KJ, Goh YJ, Hwang SH. Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway Molecules. 2020 Mar 27;25(7):. PMID: 32230890", "BibTeX": "@article{32230890, title={Lysophosphatidic Acid Inhibits Simvastatin-Induced Myocytoxicity by Activating LPA Receptor/PKC Pathway}, author={Won KJ and Goh YJ and Hwang SH}, journal={Molecules}, volume={25}, number={7}}"}}, {"_id": "31853708", "pmid": 31853708, "title": "Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure.", "journal": "Amino Acids", "authors": ["Sasani A", "Hornig S", "Grzybowski R", "Cordts K", "Hanff E", "Tsikas D", "Böger R", "Gerloff C", "Isbrandt D", "Neu A", "Schwedhelm E", "Choe CU"], "date": "2020-01-01T00:00:00Z", "doi": "10.1007/s00726-019-02812-4", "meta_date_publication": "2020 Jan", "meta_volume": "52", "meta_issue": "1", "meta_pages": "73-85", "score": 50250.023, "text_hl": "We found that @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ induced @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@ and reduced @GENE_GATM @GENE_2628 @@@AGAT@@@ expression in wildtype @SPECIES_10090 @@@mice@@@ (myocyte diameter: 34.1 +- 1.3 microm vs 21.5 +- 1.3 microm, P = 0.026; @GENE_GATM @GENE_2628 @@@AGAT@@@ expression: 1.0 +- 0.3 vs 0.48 +- 0.05, P = 0.017). ", "citations": {"NLM": "Sasani A, Hornig S, Grzybowski R, Cordts K, Hanff E, Tsikas D, Böger R, Gerloff C, Isbrandt D, Neu A, Schwedhelm E, Choe CU. Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure. Amino Acids. 2020 Jan;52(1):73-85. PMID: 31853708", "BibTeX": "@article{31853708, title={Muscle phenotype of AGAT- and GAMT-deficient mice after simvastatin exposure.}, author={Sasani A and Hornig S and Grzybowski R and Cordts K and Hanff E and Tsikas D and Böger R and Gerloff C and Isbrandt D and Neu A and Schwedhelm E and Choe CU}, journal={Amino Acids}, volume={52}, number={1}, pages={73-85}}"}}, {"_id": "19721707", "pmid": 19721707, "pmcid": "PMC2728614", "title": "Myopathy with Concurrent Tadalafil and Simvastatin", "journal": "Case Rep Med", "authors": ["Gargante MP", "Vacante M", "Russo C", "Malaguarnera M"], "date": "2009-01-01T00:00:00Z", "doi": "10.1155/2009/378287", "meta_date_publication": "2009", "meta_volume": "2009", "meta_issue": "", "meta_pages": "378287", "score": 50066.04, "text_hl": "@DISEASE_Muscular_Diseases @DISEASE_MESH:D009135 @@@Myopathy@@@ with Concurrent @CHEMICAL_Tadalafil @CHEMICAL_MESH:D000068581 @@@Tadalafil@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@", "citations": {"NLM": "Gargante MP, Vacante M, Russo C, Malaguarnera M. Myopathy with Concurrent Tadalafil and Simvastatin Case Rep Med. 2009;2009():378287. PMID: 19721707", "BibTeX": "@article{19721707, title={Myopathy with Concurrent Tadalafil and Simvastatin}, author={Gargante MP and Vacante M and Russo C and Malaguarnera M}, journal={Case Rep Med}, volume={2009}, pages={378287}}"}}, {"_id": "27750346", "pmid": 27750346, "title": "[Medication management: Simvastatin and Amlodipin - a clinically relevant drug-interaction?]", "journal": "Dtsch Med Wochenschr", "authors": ["Schröder J", "Goltz L", "Knoth H"], "date": "2016-10-01T00:00:00Z", "doi": "10.1055/s-0042-107901", "meta_date_publication": "2016 Oct", "meta_volume": "141", "meta_issue": "21", "meta_pages": "1575-1577", "score": 50062.457, "text_hl": "The highest approved dose of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (80 mg) is generally not recommended in new @SPECIES_9606 @@@patients@@@ because of increased risk of @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@.", "citations": {"NLM": "Schröder J, Goltz L, Knoth H. [Medication management: Simvastatin and Amlodipin - a clinically relevant drug-interaction?] Dtsch Med Wochenschr. 2016 Oct;141(21):1575-1577. PMID: 27750346", "BibTeX": "@article{27750346, title={[Medication management: Simvastatin and Amlodipin - a clinically relevant drug-interaction?]}, author={Schröder J and Goltz L and Knoth H}, journal={Dtsch Med Wochenschr}, volume={141}, number={21}, pages={1575-1577}}"}}, {"_id": "16442367", "pmid": 16442367, "title": "Striated muscle safety of ezetimibe/simvastatin (Vytorin).", "journal": "Am J Cardiol", "authors": ["Davidson MH", "Maccubbin D", "Stepanavage M", "Strony J", "Musliner T"], "date": "2006-01-15T00:00:00Z", "doi": "10.1016/j.amjcard.2005.08.038", "meta_date_publication": "2006 Jan 15", "meta_volume": "97", "meta_issue": "2", "meta_pages": "223-8", "score": 50059.758, "text_hl": "For all AE categories examined, the incidence of @DISEASE_Muscle_Neoplasms @DISEASE_MESH:D019042 @@@muscle@@@-related clinical and laboratory AEs or discontinuations due to @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle-related AEs@@@ was no more common in @SPECIES_9606 @@@patients@@@ taking @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ than in those taking @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ alone. ", "citations": {"NLM": "Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol. 2006 Jan 15;97(2):223-8. PMID: 16442367", "BibTeX": "@article{16442367, title={Striated muscle safety of ezetimibe/simvastatin (Vytorin).}, author={Davidson MH and Maccubbin D and Stepanavage M and Strony J and Musliner T}, journal={Am J Cardiol}, volume={97}, number={2}, pages={223-8}}"}}, {"_id": "27425755", "pmid": 27425755, "title": "Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report.", "journal": "J Clin Pharm Ther", "authors": ["Qu H", "Guo M", "Kou N", "Wu HT", "Zhang Y", "Gao ZY", "Shi DZ"], "date": "2016-10-01T00:00:00Z", "doi": "10.1111/jcpt.12419", "meta_date_publication": "2016 Oct", "meta_volume": "41", "meta_issue": "5", "meta_pages": "568-71", "score": 50057.715, "text_hl": "We report on a case of statin-associated @<m>DISEASE_Muscular_Atrophy</m> @DISEASE_MESH:D009133 @@@muscle damage@@@ that was successfully managed by simplifying the @SPECIES_9606 @@@patient@@@'s combination therapy with @CHEMICAL_Ezetimibe_Simvastatin_Drug_Combination @CHEMICAL_MESH:D000069499 @@@simvastatin-ezetimibe@@@ to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ alone. ", "citations": {"NLM": "Qu H, Guo M, Kou N, Wu HT, Zhang Y, Gao ZY, Shi DZ. Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report. J Clin Pharm Ther. 2016 Oct;41(5):568-71. PMID: 27425755", "BibTeX": "@article{27425755, title={Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report.}, author={Qu H and Guo M and Kou N and Wu HT and Zhang Y and Gao ZY and Shi DZ}, journal={J Clin Pharm Ther}, volume={41}, number={5}, pages={568-71}}"}}]}